It got approved for facial and abdominal attacks. Theoretically could vphm get approval for laryngeal attacks or attacks elsewhere? I don't think they'll bother regardless. Just seems strange the fda put in technically restrictive indications.
In the US, Cinryze was approved for prophylaxis in Oct 2008 (#msg-32795311); however, Cinryze for the acute indication is blocked by CSL’s Berinert, which has marketing exclusivity until 2016 stemming from an orphan designation and FDA approval in Oct 2009 (#msg-42409618).
Market Data 
Markets 
AI
